1065331-03-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(3R,4R)-Rel-4-Methyl-3-pyrrolidinecarboxylic acidmethylester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used as a Chiral Building Block in Organic Chemistry:
In the field of organic chemistry, (3R,4R)-Rel-4-Methyl-3-pyrrolidinecarboxylic acidmethylester is utilized as a chiral building block, enabling the creation of complex molecules with specific stereochemistry, which is crucial for the biological activity and selectivity of the resulting compounds.
Used in Peptide Production:
(3R,4R)-Rel-4-Methyl-3-pyrrolidinecarboxylic acidmethylester is employed in the production of peptides, where its unique structure and properties contribute to the formation of biologically active peptide sequences.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In asymmetric synthesis, (3R,4R)-Rel-4-Methyl-3-pyrrolidinecarboxylic acidmethylester is used as a chiral auxiliary to produce enantiomerically pure compounds, which is essential for the development of drugs with high selectivity and reduced side effects.

Upstream product

• 623-43-8 methyl crotonate 

Relevant academic research and scientific papers

Design and Synthesis of 56 Shape-Diverse 3D Fragments

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.

PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE DERIVATIVES AS PDE9 INHIBITORS

Pyrazolo[4,3-d]pyrimidin-7(6H)-one derivatives represented by the general formula (I), wherein R1 represents hydrogen atom or methyl; when R1 represents hydrogen atom, then R2 represents cyclopentyl, tetrahydropyranyl, cyclohexyl, or cyclohexyl substituted with 1 or 2 halogen atoms; when R1 represents methyl, then R2 represents cyclopentyl; R3 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, and OCH3; and 6- to 10-membered heteroaryl with 1 to 3 heteroatoms selected independently form O, N and S; and Q represents C1-C3-alkylene group, which is unsubstituted or substituted with 1 to 3 C1-C3-alkyl groups; and their salts. The compounds are PDE9A inhibitors useful as m edicaments, in particular for treatment of cognitive function disorders and neurodegenerative diseases

Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit

Starting from a hit identified by focused screening, 3-aminopyrrolidine factor Xa inhibitors were designed. The binding mode as determined by X-ray structural analysis as well as the pharmacokinetic behaviour of selected compounds is discussed.